ApoB and the lipid panel: what actually predicts heart risk
Your heart risk tracks the number of cholesterol-carrying particles in your blood, not just the cholesterol inside them. Apolipoprotein B (ApoB) counts those particles directly, which is why it, and its cheaper proxy non-HDL cholesterol, often predict cardiovascular risk more reliably than LDL cholesterol alone. This guide explains what each line on a lipid panel tells you, where the trig:HDL ratio and Lp(a) fit, how UK guidelines use QRISK3 and non-HDL, and how to raise ApoB or Lp(a) testing with your GP.
Key facts
- Every atherogenic particle (LDL, VLDL, IDL, remnants and Lp(a)) carries exactly one ApoB molecule, so plasma ApoB equals the total particle count.1
- When LDL-C and ApoB disagree, the particle count (ApoB) is the better risk marker. A systematic review found ApoB superior to LDL-C in 9 of 9 discordance analyses and superior to non-HDL-C in 7 of 9.2
- NICE uses QRISK3 (ages 25 to 84) for primary prevention, treats a 10 percent or higher 10-year risk as the threshold for offering atorvastatin 20 mg, and tracks non-HDL cholesterol, not LDL-C, on treatment.3
- Lp(a) is largely genetic and a causal risk factor. UK guidance suggests measuring it once in most people, as it changes little over a lifetime.7
Why particle count beats cholesterol content
Atherosclerosis is driven by lipoprotein particles getting trapped in the artery wall. The cholesterol they carry is the cargo; the particle is the vehicle. LDL-C measures the cargo, the cholesterol inside your LDL particles. ApoB measures the vehicles: each LDL, VLDL, IDL, remnant and Lp(a) particle carries one molecule of apolipoprotein B, so plasma ApoB is a headcount of every atherogenic particle you have.1
Most of the time the two numbers agree. The problem is when they diverge. Two people can share an LDL-C of 3.0 mmol/L while one carries far more (smaller, cholesterol-poor) particles, and therefore far more risk. This split, called discordance, is common in high triglycerides, obesity and type 2 diabetes, the groups in whom LDL-C most often understates danger. A multivariable Mendelian randomisation analysis found the causal effect of blood lipids on coronary heart disease was explained by ApoB: once ApoB was accounted for, the apparent effects of LDL-C and triglycerides largely fell away.5
Evidence strength: that ApoB is causal and the most accurate single risk marker is supported by large genetic (Mendelian randomisation) studies and consistent discordance analyses.25 What is not yet settled by outcome trials is whether treating to an ApoB target beats treating to a non-HDL or LDL target. So ApoB is the better measurer of risk, not yet a proven separate treatment goal in UK practice.
What each line on the panel actually tells you
A standard UK lipid panel reports total cholesterol, HDL, LDL (often calculated, not measured), triglycerides and now usually non-HDL. Here is what each is genuinely good for.
| Marker | What it measures | How useful for risk |
|---|---|---|
| Total cholesterol | All cholesterol, good and bad combined | Crude alone; useful inside the total:HDL ratio QRISK3 uses.3 |
| LDL cholesterol | Cholesterol in LDL particles (often estimated) | The classic target, but can understate risk when particles are small and numerous.2 |
| HDL cholesterol | Cholesterol in HDL particles | Higher tracks lower risk, but raising it with drugs has not cut events: a marker, not a lever. |
| Non-HDL cholesterol | Total cholesterol minus HDL: all atherogenic cholesterol | Strong, cheap, no fasting; the marker NICE tracks on treatment.3 |
| Triglycerides | Fat in remnant and VLDL particles | High levels flag metabolic risk; very high levels also risk pancreatitis. |
| ApoB | Total count of atherogenic particles | The most accurate single marker, especially when LDL-C and triglycerides disagree.12 |
| Lp(a) | An inherited, especially atherogenic particle | Largely genetic; an independent, causal risk factor, measured once.7 |
Non-HDL cholesterol earns its growing prominence. It captures the cholesterol in every atherogenic particle in one subtraction, needs no fasting and costs nothing extra. In the Emerging Risk Factors Collaboration, pooling 302,430 people across 68 studies, the non-HDL to HDL ratio predicted coronary heart disease essentially as well as the ApoB to ApoA-I ratio (hazard ratios of 1.50 and 1.49).4 Non-HDL is most of the value of ApoB for free, which is why NICE leans on it. For more on why an in-range number is not always right for you, see our health library.
The trig:HDL ratio: a free window on insulin resistance
Reading triglycerides and HDL together extracts more from a basic panel. High triglycerides alongside a low HDL is the fingerprint of insulin resistance, which tends to bring smaller, denser, more numerous LDL particles, the discordant picture in which LDL-C misleads. McLaughlin and colleagues showed the triglyceride to HDL ratio identifies insulin-resistant adults reasonably well against the gold-standard clamp method.6
Mind your units. The quoted ratio cut-off of about 3 to 3.5 comes from US studies using mg/dL. UK labs report in mmol/L, where the rough equivalent is around 1.0 to 1.5, so do not apply the US number to a UK result. The ratio is a prompt to look harder at metabolic health, not a diagnosis.
A high trig:HDL ratio is a prompt to check HbA1c and ApoB, since the panel is hinting at the process covered in our piece on insulin resistance and early metabolic signals.
Lp(a): the inherited number worth knowing once
Lipoprotein(a), or Lp(a), is an LDL-like particle with an extra protein attached. Levels are roughly 80 to 90 percent genetically fixed and barely shift with diet, exercise or statins. Crucially it is a causal driver of both atherosclerosis and aortic valve disease, independent of LDL-C. The HEART UK consensus statement therefore recommends measuring it, generally once, with risk rising across bands (broadly: 90 to 200 nmol/L moderate, 200 to 400 high, above 400 very high).7 No licensed drug yet lowers Lp(a) specifically (targeted therapies are in trials), but a raised result sharpens the case for treating everything else hard, and flags relatives who may share the inherited risk.
How UK guidelines actually use these numbers
NICE guideline NG238 (December 2023, replacing CG181) sets out the UK approach. Risk is estimated with the QRISK3 tool for people aged 25 to 84, combining age, sex, ethnicity, blood pressure, smoking, the total:HDL ratio and several conditions into a 10-year percentage. A score of 10 percent or more is the threshold at which atorvastatin 20 mg is offered, though it can be considered below that after discussion.3
Note what NICE does and does not use. QRISK3 uses the total:HDL ratio for the initial estimate; NICE then tracks non-HDL cholesterol, not LDL-C, to judge response, aiming for a greater than 40 percent reduction in non-HDL in primary prevention. For secondary prevention (established cardiovascular disease) the targets are an LDL-C of 2.0 mmol/L or below, or a non-HDL of 2.6 mmol/L or below.3 ApoB is not part of the routine NICE pathway, though specialist bodies increasingly favour it as the more accurate measure.2
Getting ApoB or Lp(a) tested in the UK
On the NHS a GP will usually order a standard lipid panel (now including non-HDL) and use QRISK3. ApoB is not a routine NHS test and is mostly confined to lipid clinics, so a GP may decline it for general optimisation without a clear clinical reason. Lp(a) is more often justifiable where there is premature cardiovascular disease, a strong family history or familial hypercholesterolaemia, usually via lipid-clinic referral.
Both are widely available privately without referral, typically from around 30 to 90 pounds for a single marker. If you go private, ask for a standardised assay and take the result back to your GP rather than acting on it alone. To keep any supplements or treatments organised alongside this, our stack builder can help.
- Can we calculate my QRISK3 score and look at my non-HDL cholesterol, not just LDL-C?
- My triglycerides are high and HDL low: should we check HbA1c and ask whether LDL-C understates my risk?
- Given my family history of early heart disease, would a one-off Lp(a) test, or a lipid-clinic referral, be reasonable?
- If my LDL-C and risk picture disagree, is ApoB worth measuring to settle it?
- What non-HDL reduction are we aiming for, and when should we recheck?
References
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. PMC7369156.
- Sniderman AD, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk (systematic review of discordance analyses). J Clin Lipidol. 2025. lipidjournal.com.
- NICE guideline NG238. Cardiovascular disease: risk assessment and reduction, including lipid modification. 2023. nice.org.uk.
- Emerging Risk Factors Collaboration. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA. 2009;302(18):1993-2000. PMC3284229.
- Richardson TG, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLOS Med. 2020;17(3):e1003062. PLOS Medicine.
- McLaughlin T, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-809. PMID 14623617.
- Cegla J, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 2019;291:62-70. atherosclerosis-journal.com.
This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.